Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in ...
Boston biotech Atalanta raises $97M to bring CNS drugs into clinic
Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.
The Business Journals8d
Waltham biotech plans to raise $150M in IPO this week
IPO market warms up On the same day that Sionna filed its IPO paperwork in January, Boston-based Odyssey Therapeutics Inc. also notified the SEC that it planned to kick off its own IPO process.
Sionna Therapeutics Prices Upsized Initial Public Offering
Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current ...
Psychology Today3mon
Distinctive Ray Therapeutics
My extensive background in primary care, surgical, psychiatric, and veterans' care in Boston enables me to offer a culturally attuned, down-to-earth approach, ensuring that clients feel ...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform ...
Business Insider12d
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...